Table 2 Follow-up: treatment and lifestyle modifications
From: Association of renal resistive indices with kidney disease progression and mortality
Variable | Total N = 192 | Patients with RRI < 0.7 N = 68 | Patients with RRI ≥ 0.7 N = 124 | P |
|---|---|---|---|---|
Treatment | ||||
Statin, n(%) | 124 (64.6) | 44 (64.7) | 80 (64.5) | 0.979 |
ACE inhibitor, n(%) | 26 (13.5) | 12 (17.6) | 14 (11.3) | 0.203 |
Angiotensin Receptor Blocker, n(%) | 105 (54.7) | 39 (57.4) | 66 (53.2) | 0.509 |
Thiazide, n(%) | 30 (15.6) | 8 (11.8) | 22 (17.7) | 0.293 |
CCB, n(%) | 121 (63) | 37 (54.4) | 84 (67.7) | 0.087 |
PPI, n(%) | 48 (25) | 11 (16.2) | 37 (29.8) | 0.041 |
Antiaggregant agent, n(%) | 86 (44.8) | 26 (38.2) | 60 (48.4) | 0.204 |
Beta-blocker, n(%) | 113 (58.9) | 29 (42.6) | 84 (67.7) | 0.001 |
Number of antihypertensive molecules, Mean ± SD | 2.07 ± 0.96 | 1.87 ± 0.89 | 2.18 ± 0.99 | 0.027 |
Follow-up, interventions/lifestyle modifications | ||||
Duration of follow-up, months Mean ± SD | 73.4 ± 41.5 | 85.8 ± 46.6 | 66.6 ± 36.8 | 0.002 |
Number of consultations during follow-up (before dialysis), months Median (IQR) | 5 (3–10.8) | 4 (2–6.8) | 6 (3–12) | 0.002 |
Control of hypertension < 140/90, n(%) | 108 (56.3) | 48 (70.6) | 60 (48.4) | 0.006 |
HbA1c reduction in patients with diabetes, n(%) | 46 out of 93 (49.5) | 14 out of 23 (61) | 33 out of 70 (47.1) | 0.460 |
Weight loss, n(%) | 60 (31.3) | 23 (33.8) | 37 (29.8) | 0.490 |
Smoking cessation among smokers, n(%) | 13 out of 83 (15.7) | 8 out of 32 (25) | 6 out of 51 (11.8) | 0.100 |
Compliance to salt reduction, n(%) | 82 (42.7) | 37 (54.4) | 45 (36.3) | 0.009 |